RT Journal Article
T1 A Comparative Study of Two Imaging Techniques of Meibomian Glands
A1 Diz Arias, Elena
A1 Fernández Jiménez, Elena
A1 Peral Cerda, María Asunción
A1 Gómez Pedrero, José Antonio
AB In the present study, two different meibographers, Oculus Keratograph 5M (K5M) that uses 840 nm infrared light and the Visible Light Non-Contact Meibographer (VLNCM) that uses 610 nm visible light have been used to obtain meibography images from normal and Meibomian Gland Dysfunction (MGD) population. The main objective has been to validate and demonstrate that the use of visible light is useful for observation and quantification of MG in clinical practice. Twenty participants were enrolled in this prospective study. The upper eyelids of one randomly chosen eye were used to obtain results. Forty images were captured and analysed. Three specialized observers were recruited to grade images using Pult and Riede Pult 5-degree scale, in two different sessions. Intra-observer agreement between sessions for both devices was shown. Inter-observer variability analysis showed discrepancy between meiboscores obtained from observers with K5M (p-value < 0.05), except for session 2 in the pathology group, while no statistical difference was found with VLNCM. Repeatability analysis found no statistically significant differences between sessions. Correlation between meibographers showed no statistically significant difference and a moderate correlation coefficient between meiboscores graded with the two devices. The current study suggests that VLNCM can allow MG to be properly visualized and classified in the upper eyelids.
PB Multidisciplinary Digital Publishing Institute
SN 2075-1729
YR 2023
FD 2023-03-15
LK https://hdl.handle.net/20.500.14352/73121
UL https://hdl.handle.net/20.500.14352/73121
LA eng
NO Diz Arias, E., Fernández Jiménez, E., Peral Cerda, M. A., Gómez Pedrero, J. A. «A Comparative Study of Two Imaging Techniques of Meibomian Glands». Life, vol. 13, n.o 3, marzo de 2023, p. 791. DOI.org (Crossref), https://doi.org/10.3390/life13030791.
NO Fondo Europeo de Desarrollo Regional
NO Gobierno de España
NO Banco Santander
DS Docta Complutense
RD 12 may 2025